LMNX has been the subject of several other research reports. Deutsche Bank AG reiterated a sell rating and issued a $18.00 price objective on shares of Luminex Corporation in a research report on Wednesday, January 18th. Avondale Partners started coverage on Luminex Corporation in a research report on Wednesday, October 12th. They issued an outperform rating and a $27.00 price objective for the company. Finally, Zacks Investment Research downgraded Luminex Corporation from a buy rating to a hold rating in a research report on Tuesday, November 29th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the company’s stock. Luminex Corporation has a consensus rating of Hold and a consensus price target of $22.14.
Luminex Corporation (NASDAQ:LMNX) opened at 18.46 on Tuesday. Luminex Corporation has a 52-week low of $17.57 and a 52-week high of $23.75. The company has a 50 day moving average price of $20.05 and a 200-day moving average price of $20.98. The firm has a market cap of $789.50 million, a price-to-earnings ratio of 57.69 and a beta of 0.59.
Luminex Corporation (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, February 6th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.09 by $0.02. Luminex Corporation had a return on equity of 5.53% and a net margin of 5.10%. The firm earned $72.30 million during the quarter, compared to the consensus estimate of $70.92 million. During the same quarter in the previous year, the company posted $0.56 EPS. The business’s revenue for the quarter was up 19.6% compared to the same quarter last year. Equities research analysts anticipate that Luminex Corporation will post $0.33 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally reported by sleekmoney and is owned by of sleekmoney. If you are viewing this news story on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at http://sleekmoney.com/luminex-corporations-lmnx-market-perform-rating-reaffirmed-at-william-blair/1657531.html.
In related news, Director Kevin M. Mcnamara sold 12,000 shares of Luminex Corporation stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $21.03, for a total transaction of $252,360.00. Following the completion of the sale, the director now directly owns 67,274 shares of the company’s stock, valued at $1,414,772.22. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director G Walter Loewenbaum II sold 20,000 shares of Luminex Corporation stock in a transaction on Thursday, January 26th. The stock was sold at an average price of $19.75, for a total value of $395,000.00. Following the sale, the director now directly owns 766,240 shares of the company’s stock, valued at $15,133,240. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 162,000 shares of company stock valued at $3,292,660. 6.90% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the company. New York State Teachers Retirement System boosted its stake in shares of Luminex Corporation by 5.1% in the second quarter. New York State Teachers Retirement System now owns 43,334 shares of the company’s stock worth $877,000 after buying an additional 2,100 shares during the period. Bank of Montreal Can bought a new stake in shares of Luminex Corporation during the second quarter worth approximately $1,973,000. Capital Fund Management S.A. bought a new stake in shares of Luminex Corporation during the second quarter worth approximately $229,000. Neuberger Berman Group LLC boosted its stake in shares of Luminex Corporation by 2.4% in the second quarter. Neuberger Berman Group LLC now owns 531,825 shares of the company’s stock worth $10,759,000 after buying an additional 12,524 shares during the period. Finally, Oxford Asset Management boosted its stake in shares of Luminex Corporation by 116.0% in the second quarter. Oxford Asset Management now owns 276,434 shares of the company’s stock worth $5,592,000 after buying an additional 148,462 shares during the period. 79.45% of the stock is owned by institutional investors and hedge funds.
Luminex Corporation Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/luminex-corporations-lmnx-market-perform-rating-reaffirmed-at-william-blair/1657531.html
Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.